# Effect of Early High-dose Epoetin Alfa During Cardiac Arrest (Pilot Study)

> **NCT00719498** · PHASE3 · COMPLETED · sponsor: **Janssen Cilag S.A.S.** · enrollment: 20 (actual)

## Conditions studied

- Resuscitation
- Cardiopulmonary
- Cardiac Arrest

## Interventions

- **DRUG:** Epo-alpha

## Key facts

- **NCT ID:** NCT00719498
- **Lead sponsor:** Janssen Cilag S.A.S.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** —
- **Final completion:** 2004-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2011-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00719498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00719498, "Effect of Early High-dose Epoetin Alfa During Cardiac Arrest (Pilot Study)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00719498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*